Top

Published in:

01-11-2006 | Poster Presentation

Characterization of peptide aptamers to the Anterior Gradient 2: a novel inhibitor of the tumour suppressor protein p53

Authors: A Fourtouna, E Murray, L Hayward, L Pohler, T Hupp

Published in: Breast Cancer Research | Special Issue 2/2006

Excerpt

Anterior Gradient-2 was identified using proteomic technologies as a protein overexpressed in human cancers. We show here properties of AG2 suggesting it has proto-oncogenic properties:(i) the AG2 protein and gene are unregulated in a tamoxifen resistance panel of breast cancer cells lines, (ii) cell lines overproducing AG2 have an elevated clonogenic activity in vitro and also increase cell growth in a xenograft model, (iii) AG2 protein inhibits the tumour suppressor protein p53, and (iv) AG2 localizes to the endoplasmic reticulum, suggesting a proto-onocogenic signalling pathway exists from endoplasmic reticulum to the nucleus to inhibit p53. …

Title: Characterization of peptide aptamers to the Anterior Gradient 2: a novel inhibitor of the tumour suppressor protein p53
Authors: A Fourtouna
E Murray
L Hayward
L Pohler
T Hupp
Publication date: 01-11-2006
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 2/2006
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1565

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2006

Insulin-like growth factor signalling in oestrogen nonresponsive breast cancer cells

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer

The Cambridge breast intensity modulated radiotherapy trial

Phenotypic characterization of mouse mammary epithelial stem and progenitor cells

Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes

New molecular tools and optical technologies to dissect CXCR4 function in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer